Oncotarget

Meta-Analysis:

The diagnostic and prognostic value of CHFR hypermethylation in colorectal cancer, a meta-analysis and literature review

Zhulei Sun, Juncai Liu, Hong Jing, Shu-Xiao Dong and Jiang Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:89142-89148. https://doi.org/10.18632/oncotarget.19408

Metrics: PDF 422 views  |   HTML 1001 views  |   ?  


Abstract

Zhulei Sun1,*, Juncai Liu2,*, Hong Jing1, Shu-Xiao Dong3 and Jiang Wu1

1Department of Pathology, Huaihe Hospital, Henan University, 8 Bao Bei Lu, GuLou Qu, Kaifeng 475000, China

2Department of Radiotherapy, Huaihe Hospital, Henan University, Kaifeng 475000, China

3Department of Gastrointestinal Surgery, Linyi People’s Hospital, Linyi 276001, Shandong, China

*These authors contributed equally to this work

Correspondence to:

Jiang Wu, email: jiangwumi@hotmail.com

Keywords: CHFR, methylation, biomarker, CRC, colorectal carcinoma

Received: March 13, 2017     Accepted: June 24, 2017     Published: July 20, 2017

ABSTRACT

The Checkpoint with Forkhead-associated and Ring finger domains (CHFR) is a mitotic checkpoint and tumor-suppressor gene, its loss contributes tumorigenesis of epithelial cancers including colorectal carcinoma (CRC). The diagnostic and prognostic value of CHFR promoter hypermethylation in CRC remains unclear. This study aimed to conduct a meta-analysis and literature review and investigate clinicopathological significance of CHFR promoter hypermethylation in CRC. The following online database were used: PubMed, EMBASE, and Web of Science up to March 2017. Odds Ratios (OR) and Hazard Ratios (HR) with 95% corresponding confidence intervals (CIs) were calculated. A total of seven relevant articles were available for meta-analysis which included 966 patients. The frequency of CHFR promoter hypermethylation significantly increased in CRC compared to normal colorectal mucosa tissue, pooled OR was 8.35, p < 0.00001. CHFR promoter hypermethylation was not significantly correlated to stage, OR was 1.16, p = 0.63. However, CHFR promoter hypermethylation was more frequently observed in CRC with positive lymph nodes metastasis than CRC with negative lymph nodes metastasis, OR was 0.46, p = 0.03. Additionally CHFR promoter hypermethylation was significantly related to poor overall survival in patients with CRC, HR was 0.62, p = 0.008. Based on these results, tumor CHFR promoter hypermethylation is not only a diagnostic biomarker for CRC, but also a prognostic marker. CHFR promoter hypermethylation is significantly associated with worse overall survival in patients with CRC. Our data suggested that CHFR could be a potential drug target for development of demethylation treatment for patients with CRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19408